Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 p53 lesions in leukemic transformation.

Literature DB >> 21288114

p53 lesions in leukemic transformation.

Ashot Harutyunyan, Thorsten Klampfl, Mario Cazzola, Robert Kralovics.

Abstract

Entities: Disease Gene Mutation

Mesh：

Year: 2011 PMID： 21288114 DOI： 10.1056/NEJMc1012718

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

71 in total

Review 1. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors: Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952

2. Inherited predisposition to myeloproliferative neoplasms.

Authors: Amy V Jones; Nicholas C P Cross
Journal: Ther Adv Hematol Date: 2013-08

3. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Authors: Sue Haupt; Catherine Mitchell; Vincent Corneille; Jake Shortt; Stephen Fox; Pier Paolo Pandolfi; Mireia Castillo-Martin; Dennis M Bonal; Carlos Cordon-Cardo; Guillermina Lozano; Ygal Haupt
Journal: Cell Cycle Date: 2013-05-08 Impact factor: 4.534

4. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors: Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal: Blood Adv Date: 2018-12-26

5. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Authors: Min Lu; Xiaoli Wang; Yan Li; Joseph Tripodi; Goar Mosoyan; John Mascarenhas; Marina Kremyanskaya; Vesna Najfeld; Ronald Hoffman
Journal: Blood Date: 2012-08-07 Impact factor: 22.113

6. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Authors: Frédéric Courtier; Nadine Carbuccia; Séverine Garnier; Arnaud Guille; José Adélaïde; Nathalie Cervera; Véronique Gelsi-Boyer; Marie-Joelle Mozziconacci; Jérôme Rey; Norbert Vey; Max Chaffanet; Daniel Birnbaum; Anne Murati
Journal: Haematologica Date: 2016-10-14 Impact factor: 9.941

p53 lesions in leukemic transformation.

Review 1. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

2. Inherited predisposition to myeloproliferative neoplasms.

3. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

4. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

5. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

6. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Review 7. Leveraging cancer genome information in hematologic malignancies.

8. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.

Review 9. Prognosis of Primary Myelofibrosis in the Genomic Era.

Review 10. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.